Novavax CEO on Covid Vaccine Approval, Omicron Efficacy

The transcript discusses the Nova VAX vaccine, highlighting its efficacy, stability, and global distribution capabilities. It covers the mix and match strategy with other vaccines, logistical challenges, and the response to variants like Omicron. The approval process in various countries and the importance of market strategy are also discussed. Additionally, the need for booster shots and future plans for combining the COVID and flu vaccines are explored.

What data is being collected to evaluate the Nova VAX vaccine's effectiveness against the Omicron variant?

What are the expected timelines for the approval of the Nova VAX vaccine in the United States?

How does the Nova VAX vaccine plan to integrate with seasonal vaccination strategies in the future?